(Received for publication, October 9, 1996, and in revised form, December 23, 1996)
From the Dipartimento di Biochimica e Biotecnologie Mediche,
Università degli Studi di Napoli Federico II, CEINGE
Biotecnologie Avanzate s.c.r.l., via S. Pansini 5, 80131 Naples, Italy, Laboratory of Molecular and
Cellular Neuroscience, Rockefeller University,
New York, New York 10021, and § Department of
Biochemistry, Mount Sinai School of Medicine,
New York, New York 10029
The two tandem phosphotyrosine
interaction/phosphotyrosine binding (PID/PTB) domains of the Fe65
protein interact with the intracellular region of the Alzheimer's
-amyloid precursor protein (APP). This interaction, previously
demonstrated in vitro and in the yeast two hybrid system,
also takes place in vivo in mammalian cells, as
demonstrated here by anti-Fe65 co-immunoprecipitation experiments. This
interaction differs from that occurring between other PID/PTB
domain-containing proteins, such as Shc and insulin receptor substrate
1, and activated growth factor receptors as follows: (i) the Fe65-APP
interaction is phosphorylation-independent; (ii) the region of the APP
intracellular domain involved in the binding is larger than that of the
growth factor receptor necessary for the formation of the complex with
Shc; and (iii) despite a significant similarity the carboxyl-terminal
regions of PID/PTB of Fe65 and of Shc are not functionally
interchangeable in terms of binding cognate ligands. A role for Fe65 in
the pathogenesis of familial Alzheimer's disease is suggested by the
finding that mutant APP, responsible for some cases of familial
Alzheimer's disease, shows an altered in vivo interaction
with Fe65.
The -amyloid precursor protein
(APP)1 is an integral membrane protein from
which the
-amyloid peptide is generated. The
-amyloid peptide
forms the extracellular insoluble aggregates characteristic of
Alzheimer's disease. The function of APP and the regulation of the
proteolytic events generating the
-amyloid peptide are still
unknown. APP was expected to be involved in signal transduction processes, because of its transmembrane topology. Three main isoforms of APP exist, generated by alternative splicing (APP770,
APP751, and APP695) and all possessing the same
intracellular domain (reviewed in Ref. 1). Although little is known
about the putative extracellular ligand(s) for APP, several results
describe the interaction of its intracellular domain with other
proteins. These include the interaction with the heterotrimeric G
protein Go (2), a 59-kDa ubiquitously expressed protein named APP-BP1
(3), the X11 protein (4), the neuron-abundant Fe65 protein, and an
Fe65-like protein (4-6). It was shown that intact APP binds to
oligomeric Go protein and that the intracellular region of APP spanning
residues 657-676 activates Go (2, 7). Furthermore, the interaction of
APP with a monoclonal antibody directed against its extracellular domain mimics a ligand-receptor binding that triggers Go activation (7). APP-BP1 interacts both in vitro and in vivo
with the carboxyl-terminal region of APP, which represents its
intracellular domain. This protein is homologous to the product of the
Arabidopsis auxin resistance gene AXR1 and to a
Caenorabditis elegans protein of unknown function (3).
The Fe65 gene is mainly expressed in the neurons of specific regions of the mammalian nervous system (8, 9) and encodes a protein containing two different types of protein-protein interaction domains: the WW domain (reviewed in Ref. 10) and the phosphotyrosine interaction/phosphotyrosine binding (PID/PTB) domain (reviewed in Ref. 11). The latter was found in the oncoprotein Shc (12, 13), in its relatives ShcB-Sck and ShcC (14), in other apparently unrelated proteins, such as Numb, X11, and Dab (15), and in insulin receptor substrate 1 (IRS-1) and IRS-2 (16, 17). The PID/PTB domains interact with phosphotyrosine residues located in the intracellular domains of growth factor receptors, such as EGF-R, trkA, and platelet-derived growth factor receptor in the case of Shc (13) and insulin receptor and interleukin 4 receptor in the case of IRS-1 (16). In contrast, the Fe65 region containing the two PID/PTB domains was demonstrated to interact with the intracellular domain of APP (5).
All the PID/PTB domains present in the Shc family, IRS-1, and Fe65
interact with intracellular regions of membrane proteins containing the
consensus motif XNPXY (where
is
hydrophobic and X is any amino acid). However, Fe65
possesses at least two unique characteristics: (i) although all the
known members of the PID/PTB family contain only one PID/PTB element
(13), Fe65 is an exception, because its sequence interacting with APP
shows two consecutive PID/PTB domains; and (ii) although the Tyr
present in the consensus sequence of all the growth factor receptors
must be phosphorylated to allow the binding to the PID/PTB domain of Shc and IRS-1 (18), no experimental result supports the possibility that the Tyr of the consensus motif present in the intracellular domain of APP can be phosphorylated.
Another important aspect of APP is the interaction between Fe65 and the mutant forms of APP found in some forms of familial Alzheimer's disease (FAD). These point mutations involve residues in the juxtamembrane and transmembrane regions of APP (19), and it can be hypothesized that they could cause conformational changes of the APP intracellular domain or defects in the transduction phenomena involving APP, which in turn could affect the interaction with Fe65.
In this report we show that the PID/PTB region of Fe65 significantly diverges from the structurally related domains present in the family of the growth factor receptor-binding proteins, including Shc and IRS-1. Furthermore, we document that some mutant forms of APP, found in FAD, interact poorly in vivo with Fe65, suggesting the involvement of this molecule in the genesis of the Alzheimer's disease phenotype.
The various Fe65
cDNA fragments used in this study were obtained by amplification of
the FE65 cDNAs described previously (8, 20) by polymerase chain
reactions. The fragment corresponding to the Fe65 cDNA encoding
both PID/PTB domains (Fe65-PID1.2, codons 312-612) (5), as well as the
deletion mutants Fe65-PID1 (codons 312-479), Fe65-C1 (codons
312-508), Fe65-
C2 (codons 312-577), Fe65-PID2 (codons 484-612),
and Fe65-
N1 (codons 377-612) and the Shc PID/PTB domain (Shc-PID,
codons 46-232) were obtained by direct amplification of the FE65 or
Shc cDNAs with specific oligonucleotide primers (CEINGE). The FE65
fragments containing internal deletions, i.e. Fe65-
Sp.
(codons 312-456 and 484-612) and Fe65-
Sp. C3 (codons 312-424 and
484-612), as well as the Fe65-Shc chimeric constructs, i.e.
Fe65-
C1-Shc (codons 312-508Fe65 and
84-232Shc), Fe65-
C2-Shc (codons
312-577Fe65 and 154-232Shc), Shc-
C-PID1
(codons 46-193Shc and 445-457Fe65), and
Shc-
C-PID2 (codons 46-193Shc and
600-612Fe65), were obtained by overlap extension of the
corresponding polymerase chain reaction-generated fragments containing
complementary sequences (21). The recombinant constructs were obtained
by ligation of the polymerase chain reaction fragments digested with
appropriate restriction enzymes and purified from agarose gels with the
QIAEX gel extraction kit (Qiagen) in the yeast pGBT10 vector (Clontech)
and/or in pGEX vectors (Pharmacia Biotech Inc.) by standard cloning
procedures and sequenced by using the Sequenase kit (U. S. Biochemical
Corp.).
PC12 cells were cultured in Dulbecco's modified minimal essential medium (ICN) supplemented with 10% fetal calf serum (Hyclone), 5% horse serum (Life Technologies, Inc.), and 1% penicillin/streptomycin mixture (ICN). For the metabolic labeling, exponentially growing PC12 cells were starved of methionine and cysteine for 30 min and then incubated in the presence of 80 µCi/ml [35S]methionine/[35S]cysteine mixture (Promix; Amersham Corp.; 1000 Ci/mol) for 3 h.
COS cells were cultured in Dulbecco's modified minimal essential medium supplemented with 10% fetal calf serum and transfected by electroporation with the Fe65 cDNA cloned into the pRc/CMV vector (Invitrogen). A431 cells were cultured in Dulbecco's modified minimal essential medium supplemented with 5% fetal calf serum and 1% antibiotic mixture. For EGF stimulation, confluent cultures of A431 cells were starved from serum for 72 h, and then EGF (100 ng/ml, Boehringer Mannheim) was added for 5 min at 37 °C. The cell lines expressing the wild-type (wt) and mutant APP were derived from a Chinese hamster ovary (CHO) line stably transfected with the wt APP751 and the following natural APP mutants containing the indicated missense mutations: E693Q, V717I, and K670N/M671L. These lines were gifts from Dr. Eddie Koo (Harvard Medical School, Boston, MA) and were cultured in Dulbecco's modified minimal essential medium, 10% fetal calf serum, and 1% antibiotics.
For the preparation of the cellular extracts, monolayer cultures were washed twice with cold phosphate-buffered saline and lysed at 4 °C in lysis buffer as described (5). The extracts were then clarified by centrifugation, and their protein concentration was determined by the Bio-Rad protein assay following the manufacturer's instructions.
Antibodies, Immunoprecipitations, and Western BlotsThe anti-APP monoclonal antibody used for the immunoprecipitations was 6E10 (22), whereas polyclonal antibody 369 (23) was used for the detection of APP in immunoblots; the 421 monoclonal antibody (Oncogene Science), specific for the p53 protein, was used as a control in the immunoprecipitations. The anti-Fe65 polyclonal antibody was raised in rabbits by using a glutathione S-transferase GST-Fe65 fusion protein (Fe65 residues 201-236) as an immunogen. For the immunoprecipitations, the cellular extracts were incubated with appropriate dilutions of the different antibodies for 1 h at 4 °C, and then protein A-Sepharose resin (Pharmacia, 30 µl/sample) was added to the extracts for collection of the immunocomplexes. The proteins were eluted with a buffer containing 50 mM Tris/Cl, pH 6,8, 2% SDS, 10% glycerol, 100 mM dithiothreitol, and 0.01% bromphenol blue, resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to Immobilon-P membranes (Millipore) according to the manufacturer's instructions. For the Western blot experiments, the filters were blocked in 2% nonfat dry milk in TBS-T solution (20 mM Tris/HCl, 150 mM NaCl, 0.05% Tween-20, pH 7.5) and incubated with appropriate dilutions of the primary antibody for 1 h at room temperature. The excess antibody was removed by sequential washing of the membranes in TBS-T, and then a 1:2000 dilution of horseradish peroxidase-conjugated protein A (Amersham) was added to the filters for 1 h at room temperature. Filters were washed and the signals detected by chemiluminescence using the ECL system (Amersham).
Expression in Escherichia coli of the Recombinant Proteins, Pull-down and Peptide Competition Assays, and Surface Plasmon ResonanceThe constructs obtained by the cloning of the
polymerase chain reaction fragments in the pGEX vectors were used to
transform E. coli cells (BL21 strain). The resulting
colonies were grown in LB broth, and the synthesis of the various GST
fusion proteins was achieved by the induction of exponentially growing
cultures with 0.25 mM
isopropyl-1-thio--D-galactopyranoside for 3 h at 30 °C. The cells were harvested by centrifugation and lysed by sonication in phosphate-buffered saline (1.5 mM
KH2PO4, 8 mM
Na2HPO4, 27 mM KCl, 137 mM NaCl). The recombinant proteins were purified with
glutathione-Sepharose resin (Pharmacia) following the instructions of
the manufacturer.
For the pull-down assay, glutathione-Sepharose beads (Pharmacia, 10 µl/sample) were saturated with appropriate amounts of the recombinant proteins in phosphate-buffered saline containing 1 mM dithiothreitol and incubated with the cell extracts (500 µg/sample) for 2 h at 4 °C. Unbound proteins were removed by washing the beads with lysis buffer, whereas the bound proteins were eluted and resolved by SDS-PAGE. Labeled proteins were visualized by fluorography of the gels with Amplify (Amersham) following the manufacturer's instructions, whereas unlabeled proteins were revealed by specific antibodies in Western blot experiments.
For the pull-down competition assay, 35S-labeled proteins from PC12 extracts (500 µg/sample) were incubated with GST or GST-Fe65 fusion protein (10 µg) bound to glutathione-Sepharose beads in the presence (100-fold molar excess) or the absence of the competing peptides. After washing the resin, the protein samples were resolved on an 8% SDS-PAGE gel and visualized by autoradiography.
Surface plasmon resonance experiments were carried out on a BIAcore Biosensor apparatus (Pharmacia), and analysis was carried out with BIAevolution software, version 2.0 (Pharmacia). A peptide corresponding to the carboxyl-terminal-most 49 amino acids of the APP cytoplasmic domain was immobilized by a terminal cysteine. All binding experiments were performed at 25 °C. GST fusion proteins were cleaved from the GST with thrombin (10 cutting units/400 µl of resuspended beads, Sigma), the thrombin and GST were removed, and the proteins were then used for binding. Either PID1 or PID2 was added at concentrations of 0.31, 0.625, 1.25, and 2.5 µM in 10 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 0.05% P-20 surfactant. The association, dissociation, and equilibrium constants were determined based on the assumption that the kinetics were first order.
Yeast Transformation andYeast
cells, Hf7c strain (24), were grown under standard conditions in
synthetic medium without uracyl. Hf7c competent cells were prepared
from exponentially growing cultures by the lithium acetate method (25)
and co-transformed with the various Fe65 PID/PTB domain mutants cloned
in the GAL4 DNA binding domain-containing vector pGBT10 and the plasmid
pL.1, containing a cDNA fragment encoding for the
carboxyl-terminal, intracellular region of the human -amyloid
precursor protein (residues 664-695) fused to the GAL4 activation
domain (5). The pGBT10-derived plasmids carry the Trp-selective marker,
whereas the pL.1 construct carries the Leu-selective marker; on
co-transfection of each of the pGBT10-derived plasmids with pL.1, the
transformants harboring both plasmids were selected on
Trp
/Leu
plates, and the ability of the
encoded proteins to form a functional GAL4 hybrid was tested by plating
replicas of the colonies on His
/Trp
/Leu
plates. The
-galactosidase assay was performed on all of the above described
co-transformants on Trp
/Leu
plates overlaid
with nitrocellulose filters as described (5).
The screening of a cDNA library from
human brain using the two hybrid system in yeast and pull-down
experiments using GST-Fe65 fusion proteins demonstrated that the region
of Fe65 from amino acid 312 to amino acid 612, which contains two
motifs with sequences that can be aligned to the Shc PID/PTB domain,
interacts with the intracellular domain of APP and APLP1 (5). To
evaluate whether this interaction also takes place with the native
full-length proteins in intact cells, we first generated an anti-Fe65
antibody directed against a Fe65 fragment from amino acid 201 to amino acid 236, synthesized in E. coli. Fig.
1A shows that the Western blot of protein
extracts from PC12 cells with this antibody visualizes a thick protein
band of about 90 kDa. The Western blot of a "long-migrating gel"
demonstrates four bands with molecular masses that range between 85 and
95 kDa. The same four bands were observed in COS cells transfected with
the Fe65 cDNA (Fig. 1A, lane 5), thus suggesting that
the protein heterogeneity is due to posttranslation modifications and
not to alternative splicing or the cross-reaction of the antibody with
related proteins.
Immunoprecipitation experiments were performed in CHO cells, stably expressing the full-length APP751 cDNA and transiently transfected with Fe65 cDNA, under the control of a strong housekeeping promoter. Protein extracts from these cells were incubated with a monoclonal antibody directed against the extracellular domain of APP, and the immunocomplexes were precipitated and analyzed by Western blot using the Fe65-specific antibody. Fig. 1B shows that Fe65 can be found in the complexes immunoprecipitated by the anti-APP antibody and not in the proteins immunoprecipitated by an unrelated monoclonal antibody (antibody 421, directed against the p53 protein). Similarly, APP is present in the proteins co-immunoprecipitated with Fe65 by the anti-Fe65 antibody and not in the control immunoprecipitation performed with the preimmune serum.
Fig. 1C shows that the interaction between Fe65 and APP also occurs at physiological concentrations of these proteins in PC12 cells. In fact, the Western blot with anti-APP antibody 369 identified this protein in the immunocomplexes containing the Fe65 protein.
Fe65 Interacts with APP in a Phosphorylation-independent Fashion, and the Interaction Motif Is Longer than theIt was clearly demonstrated by competition experiments
that Shc binds, through its PID/PTB domain, to activated growth factor receptor in a tyrosine phosphorylation-dependent manner
(18). Synthetic peptides covering different regions of the APP
intracellular domain have been tested for their ability to compete for
the binding between Fe65 and APP. Fig. 2 shows that
neither an 11-amino acid-long peptide (residues 681-691 of
APP695) nor a 20-amino acid-long peptide (residues 675-694
of APP695) is able to compete for the Fe65-APP interaction,
whereas the 32-amino acid-long peptide, covering the intracellular
domain of APP695 from residues 664-695, corresponding to
the sequence encoded by the pL.1 cDNA clone isolated in the two
hybrid system screening (5), efficiently competes for the binding of
the GST-Fe65 fusion protein with PC12 35S-labeled
proteins.
In the case of the Fe65-APP interaction the tyrosine phosphorylation of
the XNPXY motif has no effect; as shown in
Fig. 2, the tyrosine-phosphorylated 11- and 32-mer peptides show the
same behavior as the corresponding unphosphorylated versions. In fact, the 11-mer phosphopeptide is unable to compete, whereas the 32-mer phosphopeptide does, on the contrary, compete.
Therefore, in contrast to what was observed for the other PID/PTB
domains (26), the interaction of Fe65 and APP is not dependent on the
phosphorylation of the Tyr present in the
XNPXY motif of APP. This observation could be
explained in light of the results obtained from NMR analysis of the
Shc-
XNPXY peptide complex (27), which allowed
the identification of three positively charged amino acids
(Arg67, Lys169, and Arg175;
double underlined in Fig. 3) interacting with
the negatively charged phosphate moiety of the phosphotyrosine. These
three residues are conserved in all the members of the PID/PTB Shc
family (27), whereas (see the alignment of Fig. 3) they are not
conserved in the PID/PTB domains of Fe65. Similarly, in other sequences
related to Fe65, present in the sequence data banks as expressed
sequence tags, these basic residues are not conserved, supporting the
hypothesis that the proteins encoded by these Fe65-like genes also
interact with unphosphorylated ligands.
Binding Efficiency of the Two PID/PTB Domains of Fe65
The
most evident difference between Fe65 and the other proteins possessing
a PID/PTB domain is that two consecutive segments of Fe65 can be
aligned to the PID/PTB module of Shc. These segments are located at the
carboxyl-terminal half of Fe65 from amino acid 312 to amino acid 612 and are separated by 27 amino acids. We evaluated the possible
redundancy of one of the two elements by constructing GST-Fe65 fusion
proteins containing only the PID1 or the PID2 element (the amino- and
carboxyl-terminal, respectively). The pull-down experiments reported in
Fig. 4A show that PID1 is unable to interact
with APP from PC12 cells, compared with the complete PID/PTB region of
Fe65. In contrast, PID2 alone efficiently interacts in vitro
with APP as the complete PID1.2 region of Fe65. This result was
confirmed by testing the activity of PID1 and PID2 fused to the DNA
binding domain of GAL4 in the two hybrid system in yeast, in which only
PID2 is able to interact with the intracellular domain of APP fused to
the activation domain of GAL4 (see Fig. 4B), although at a
lower efficiency compared with the complete PID1.2 region of Fe65.
The binding of Fe65 to APP was further explored by testing the
efficiency of GAL4-Fe65 constructs lacking small fragments at the amino
terminus or the carboxyl terminus to bind APP. As shown in Fig.
4B, the deletions at the carboxyl terminus (Fe65-C1 and
Fe65-
C2) are sufficient to completely prevent the interaction, whereas the amino-terminal deletion of PID1 resulted in a decreased efficiency of interaction. Interestingly, the internal deletion removing the 27-amino acid-long spacer resulted in a mutant protein (Fe65-
Sp.), which completely retains the ability to interact with
APP. A longer internal deletion, involving the PID1 carboxyl terminus
(Fe65-
Sp. C3) again resulted in a phenotype suggesting a decreased
interaction with APP (see Fig. 4B).
Surface plasmon resonance analysis of the binding of the PID/PTB
domains of Fe65 to the cytoplasmic tail of APP support the aforementioned observations that: (i) PID2 is sufficient for binding to
APP; (ii) PID1 is unable to bind to APP; and (iii) tyrosine phosphorylation of APP is not required for the interaction (see Fig.
5). In these experiments, measurements were taken of the binding of recombinant Fe65 PID1 or PID2 to an immobilized synthetic peptide corresponding to the last 50 amino acids of APP. Although PID1
does not bind at any concentration tested (see Fig. 5A), the
interaction of PID2 with APP is dose-dependent (see Fig.
5B). The ka, kd, and
Kd values for PID2 binding to APP were determined to
be 9.3 × 104 M1
s
1, 3.3 × 10
2 s
1, and
488 nM, respectively.
The PID/PTB Domains of Fe65 Do Not Share Any Functional Similarity with Shc
The above-reported data suggest that the PID/PTB domains
of Shc and Fe65 are significantly divergent. According to these
functional observations, the alignment reported in Fig. 3 shows that
large segments of Fe65 and Shc are very poorly conserved, largely
because PID1 and PID2 domains of Fe65 are shorter than Shc, so that,
for example, it is impossible to find in both of the Fe65 PID/PTB structures any sequence corresponding to the region including the
2 helix of Shc, as determined by NMR analysis (27). The strongest similarity among Shc and Fe65 PID/PTB domains is restricted at the level of the sequence corresponding to the
3
structure of Shc. This sequence similarity is confirmed by the
computer-assisted analysis of the Fe65 secondary structure, which
predicts, with a very high score, three extended structures and, in the
region aligned to the
3 region of Shc, a helical
structure (see Fig. 3). To evaluate whether at least this last region
could be interchangeable between Shc and Fe65, we constructed chimeric
proteins in which the carboxyl-terminal region of Fe65 PID2 is
substituted by the corresponding carboxyl-terminal region of Shc, and,
vice versa, the carboxyl-terminal structure of Shc is substituted by
the carboxyl-terminal part of either Fe65 PID1 or PID2. These chimeric
proteins were tested for their ability to interact with APP or EGF
receptor, respectively. In the first case, as shown in Fig.
6A, the yeast two hybrid system assay showed
no interaction between the intracellular domain of APP fused to the
GAL4 trans-activation domain and two Fe65-Shc chimeras fused to the
GAL4 DNA binding domain. Similarly, the interaction of Shc and the EGF
receptor is prevented by the presence of either PID1 or PID2
carboxyl-terminal regions in the place of that of Shc. In fact, the
proteins from A431 cells treated with EGF, co-precipitated with GST-Shc
wild-type, Shc-
C-PID1, or Shc-
C-PID2 (see Fig. 6B),
were analyzed by Western blot using an anti-phosphotyrosine antibody;
this experiment showed that EGF-R interacts only with GST-Shc wild-type
protein.
Although the two PID/PTB domains of Fe65 share the same differences with Shc, their nucleotide sequence homology and the degree of amino acid sequence similarity are very low, therefore, they are probably not repeated sequences generated by an internal duplication of the gene. However, there are some structural characteristics that distinguish the PID/PTB domains of Fe65 from those of the Shc family. These include the already mentioned absence of the basic residues involved in the interaction with the phosphate of the phosphotyrosine, a cysteine that substitutes in both the PID/PTB domains of Fe65 and in the Fe65-like sequences (6) present in the Sequence Data Bank (accession numbers R67159[GenBank] and T54909[GenBank]), and the Phe198 of Shc, which is conserved in all the members of the Shc PID/PTB family (see Ref. 15; Fig. 3, bold). The mutation of this Phe198 of Shc impairs both in vitro and in vivo the binding activity of Shc (15), and this is confirmed by the results of the experiments showing that the two Shc-Fe65 chimeras, in which the carboxyl-terminal structure of Shc is substituted by the carboxyl-terminal sequence of either PID1 or PID2 of Fe65, are completely unable to bind the EGF-R, despite a significant degree of similarity among the three sequences in this region. Similarly, the Fe65-Shc chimera, in which the carboxyl-terminal segment of PID2 is deleted and substituted by the corresponding carboxyl-terminal sequence of Shc, loses the ability to interact with APP, thus suggesting that the carboxyl-terminal region of PID2 plays an important role in the interaction with APP.
In Vivo Interaction of Fe65 with APP Mutant Forms Found in Alzheimer's PatientsThe familial Alzheimer's mutants of APP
are represented by missense mutations of the Val717 residue
changed to Ile, Phe, or Gly residues, Glu693, or
Lys670 and Met671 (APP770) (19).
Although these mutants are responsible for only a few cases of FAD,
they represent a clear molecular link between -amyloid deposition
and the FAD genotype. To gain information about the molecular basis of
FAD, we addressed the question of whether Fe65 and mutant APPs
interact. To this end, CHO cells, stably expressing wt or mutant APP,
were transiently transfected with the Fe65 cDNA, and 48 h
after the transfection, the cell extracts were incubated with the
anti-Fe65 antibody. The immunoprecipitated proteins were assayed by
Western blot using the anti-APP and anti-Fe65 antibodies. The result
reported in Fig. 7A shows that, despite the
very similar amount of Fe65 in the immunoprecipitates from the
different cell lines, the mutant forms of APP associate with Fe65 with
a lower efficiency, compared with that shown by the wt APP. This is
particularly evident in the case of the
Lys670-Met671 (APP770) double
mutation, also known as the Swedish mutation.
The results of the experiments aimed at the definition of the APP sequence interacting with Fe65 indicate that all the examined APP mutations are located outside the sequence involved in the interaction (i.e. from residue 664 to residue 695). This is in agreement with the observation that the mutant forms of APP expressed in CHO cells are able to associate and co-precipitate in vitro with a GST-Fe65 fusion protein with the same efficiency as the wt form (see Fig. 7B).
The decreased interaction efficiency between Fe65 and the Alzheimer's
mutant forms of APP is particularly intriguing. The examined
APP770 mutations (V717F, E693Q, and K670N/M671L) take place
at the level of the juxtamembrane and transmembrane domains of the
protein, and it can be speculated that, as in the case of other
integral membrane proteins, such as EGF-R (28) and insulin-like growth
factor I receptor (29), a point mutation in this region is able to
alter the transduction mechanisms. There are some data suggesting a
role for APP in transducing extracellular signals through the
activation of the G protein Go, and very recently it was observed that
the APP mutants (V642I/F/G) are constitutively active Go-linked
receptors (30). The activation of Go involves the segment of the APP
intracellular domain from His657 to Lys676
(APP695) probably through a direct interaction with the
oligomeric G protein (2). The comparison of these data with our results suggests that the interaction domains of APP with Go protein and with
Fe65 probably overlap. In fact, the region of the intracellular domain
of APP interacting with Fe65 is longer than the simple XNPXY element that is sufficient to mediate
the interaction of Shc or IRS-1 with growth factor receptors. The
peptides extended up to
6 (APP681-691) and
12 (APP675-694)
residues from the Tyr of the
XNPXY element of
APP are unable to significantly compete for the binding to Fe65;
therefore, the shortest sequence that efficiently binds to Fe65 is that
encoded by the L.1 clone previously isolated by the yeast two hybrid
screening and spanning the APP intracellular domain from residue 664 to
residue 695 (5). This means that there are about 12 amino acids of APP
common to the Fe65 and the Go interaction domains.
An intriguing scenario concerns APP trafficking between the axonal membrane and the intracellular vesicular compartments (31). It is important to note that the NPXY motif, contained in the APP-Fe65 interaction sequence, has been known for a long time as an internalization signal for membrane proteins (32), and Fe65, possessing two protein-protein interaction domains (WW and PID/PTB), is a good candidate to be an adaptor molecule between APP and the cytoskeletal structures.
We thank A. Di Donato for helpful discussion, E. Koo for the kind gift of the CHO lines expressing wt and mutant APP, and P. G. Pelicci for the Shc cDNA.